The immunoprophylactic effect of chemically inactivated Pseudomonas aeruginosa extoxin A in experimental pseudomonas infections was studied. Exotoxin A toxoids were prepared by Formalin (f-TXD) or glutaraldehyde (g-TXD) treatment. Immunization of mice with three or four doses (10 ,ug each) of f-TXD and the synthetic adjuvant N-acetylmuramyl-L-alanyl-D-isoglutamine (50 ,g) induced high levels of antiexotoxin A antibodies as measured by passive hemagglutination assay and enzyme-linked immunosorbent assay. Immunization with toxoid alone did not elicit antitoxin. A significant increase in survival time and survival rate (P < 0.01) was seen in immunized (f-TXD) and in burned and infected mice (50 to 85%) as compared with control mice immunized with formalinized bovine serum albumin (6 to 20%). Virtually 100% survival was obtained when preinfection immunization was combined with single-dose gentamicin treatment within 24 h of infection. Immunization with g-TXD increased survival time (P < 0.01) but did not consistently increase survival rate, and the results were not as satisfactory as those with formalinized exotoxin. The data presented indicate that active immunization with formalinized exotoxin A toxoid and adjuvant induced protective immunity to various degrees against infections in mice and could be potentially useful in prophylaxis of P. aeruginosa infections.
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Previous studies have shown that Pseudomonas aeruginosa exotoxin A (3, 4, 18, 22, 26) is an important virulence factor in experimental pseudomonas infections (27, 29, 30, 38, 42) and that passive immunization against exotoxin A confers a significant degree of protection (25, 29, 30, 38, 40) . In human infection, high serum antitoxin levels have been correlated with a greater chance of survival (8, 37) . These results suggest that active or passive immunization against exotoxin A may be of value in the prophylaxis and treatment of P. aeruginosa infections. However, protection against experimental infection by exotoxin A toxoid of no or very limited toxicity has not yet been demonstrated.
Our studies were prompted by the findings of Abe et al. (1) that a preparation of Formalintreated exotoxin A protected mice against purified exotoxin A. We used a somewhat similar preparation to evaluate its immunoprophylactic potential in a burned-mouse P. aeruginosa infection model (16, 32, 100 ,ug of g-TXD plus 500 ,ug of protamine sulfate per ml, was absorbed on an aluminum-phosphate precipitate (3 mg/ml).
Control protein preparations used to immunize controls were prepared from bovine serum albumin (BSA) (Miles Laboratories, Inc., Kankakee, Ill.) by treating comparable concentrations of BSA in an identical manner by the Formalin (f-BSA) or the glutaraldehyde (g-BSA) procedure.
Immunization. The initial i.v. injection (0.1 ml given) on day zero with or without adjuvant, as indicated, was followed by comparable injections into the muscle of the right hind leg. Control mice received either f-BSA or g-BSA instead of toxoid (with or without adjuvant according to the experiment) or Nacetylmuramyl-L-alanyl-D-isoglutamine (MDP) alone. At various times, the mice were anesthetized with methoxyflurane (Pittman-Moore, Inc., Washington Crossing, N.J.), bled by the retroorbital procedure (<0.5 ml), and immediately injected subcutaneously with 0.5 ml of Ringer-lactate (Travenol Laboratories, Inc., Deerfield, Ill.) to replace the lost fluids. Serum was separated by centrifugation and stored at -20°C.
Mouse infection model. The Holder and Jogan (16) and Stieritz and Holder (41) burned-mouse infection model modified as previously described (32) The adenosine diphosphate-ribosyltransferase (ADPR) assay previously described (9) was used to determine the enzymatic activity of exotoxin A and the residual activity of the toxoids.
Serum enzyme assays, aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT), were determined on a Gilford 3500 computer-directed analyzer (Gilford Instrument Laboratories, Inc., Oberlin, Ohio). Guinea pig skin reactions were determined as previously described (35) . A checkerboard pattern of 2-cm squares was drawn on each guinea pig back, and 0.1 ml of exotoxin A, pyrogen-free saline, toxoid, or BSA control toxoid was injected intradermally. The skin reactions were scored at 24, 48, and 72 h.
Pathological examinations. Mice were killed by cervical dislocation, and organs (liver, kidneys, spleen, lungs, and heart) were immediately excised and placed in Telley fixative (70% ethanol-Formalin-glacial acetic acid, 20:1:1). Sections were stained with hematoxylin and eosin. The slides were examined without reference to the experimental protocol.
Statistical analysis. Survival rates of test animals within an experiment were compared by using the Wilcoxon rank sum test as described by Bradley (2).
The P values were computed by using normal approximation with continuity correction. The P values are consistent with those drawn from available Wilcoxon rank sum test tables. The LD50 was calculated by the Spearman-Karber method described by Finney (12) .
The LD50 values and survival between groups were compared by the two-tailed Student t-test. (18) was observed between the intact exotoxin A molecule and the toxoid. The toxoid also showed a reduction at least 2,000-fold in the necrotizing activity of guinea pig skin ( Table 1) . The minimal detectable reaction (3 mm) was seen with 20 ug of toxoid as compared with 3 to 5 mm with 0.005 ,ig of exotoxin A. In our cytoxicity assay, the LD5o for exotoxin A was about 0.5 ng/ml for L cells, but no cytoxic effects were observed with the highest dose (100 ng/ml) of toxoid tested (Table 1) .
No pathological changes were seen in organs (liver, kidneys, spleen, lungs, and heart) of mice given 10- (Fig. 3) . After the third injection, mice were protected against at least 100 LD50 (highest dose tested) of purified exotoxin A given i.v. In all further experiments with f-TXD, unless otherwise noted, 10 ,ug of formalinized protein plus 50 ug of MDP was administered according to the above schedule.
After immunization was completed, after the third or fourth injection, mice were traumatized and infected with either one of two toxigenic P. aeruginosa strains (PA103 or PA220) or with a nontoxigenic mutant of PA103, PA103-29 ( Table  3 ). The survival of f-TXD-immunized mice challenged with the toxigenic strains was 50 to 85%, which was significantly greater than survival of the control mice immunized with f-BSA (P < 0.01). No significant differences in survival were seen between the f-BSA group and the other two control groups, i.e., mice treated with MDP alone or untreated (data not shown). When f-TXD-immunized mice were infected with the nontoxigenic strain PA103-29, the survival rate between f-TXD and f-BSA groups was the same (P > 0.05; Table 3 ), indicating that the protection elicited by f-TXD in previous experiments is exotoxin A specific. The deaths of the mice infected with the nontoxigenic strain can probably be attributed to other pseudomonas virulence factors such as endotoxin or slime (23, 39, 45) . Regardless of the role of exotoxin A, it seems reasonably clear from work in our as well as other laboratories that it is only one of a number of toxic substances produced by the organism (29) . The protective effect of immunization with f-TXD was indicated by another series of experiments. Mice immunized with f-TXD had significantly higher LD50 (P < 0.01) than the control group (Table 4) . Thus, in our system, immunization with f-TXD and MDP resulted in an exotoxin A-specific protection against P. aeruginosa infections.
Immunization with g-TXD. We also tested the efficacy of a glutaraldehyde toxoid prepared mental P. aeruginosa infections in mice. As demonstrated by its ability to elicit antibody production in experimental animals (4) and in patients with P. aeruginosa infections (8, 36) , native exotoxin A appears to be a good immunogen. However, the Formalin-lysine treatment apparently reduces its immunogenicity since no antitoxin response was elicited by the toxoid alone. To stimulate antitoxin production, both high doses (10 ,tg) and an adjuvant (MDP or Freund complete adjuvant) were required. After either three or four injections of f-TXD and MDP, a significant protection against P. aeruginosa infections was demonstrated. The survival rate of f-TXD-immunized mice was about 50 to 85% greater than the survival of control mice immunized with f-BSA (P < 0.01), and the LD50 of immunized (f-TXD) mice was significantly higher than that of controls (P < 0.01). The protective immunity was exotoxin A specific. treated control (f-BSA) mice, a consistent and significant increase in survival of gentamicintreated, immunized (f-TXD) mice over the immunized but untreated mice was seen (Fig. 4) . Virtually 100% survival was obtained with gentamicin treatment of f-TXD-immunized mice. Similar results were obtained with g-TXD-immunized mice (Fig. 5) . The increased survival of gentamicin-treated, g-TXD-immunized over gentamicin-treated, g-BSA-immunized mice again suggests that some protection as a result of g-TXD immunization does occur. It is obvious that immunization with exotoxin A toxoids not only increases survival, but also greatly enhances the effectiveness of chemotherapy. Variable results were obtained with g-TXD. The survival time of infected mice immunized with g-TXD was consistently longer than the survival of control mice immunized with g-BSA (P < 0.001). The LD50 values of the former group were also higher than those of the controls (P < 0.02). Nonetheless, the overall survival rate of g-TXD-immunized mice could not be significantly and repeatedly increased. Depending on the experiment, the survival of immunized mice (g-TXD) varied from 0 to 30% above that of the controls (g-BSA). Thus, the efficacy of g-TXD does not appear to be as good as that of f-TXD.
The observation that the survival of mice imnmunized with g-TXD was not as satisfactory as that of mice immunized with f-TXD, even though both groups had similar antibody levels, is somewhat puzling. in vivo antitoxin levels will be reduced, and the host will be overwhelmed by the toxic effects of exotoxin A and die. In contrast, in control, nonimmune infected animals, exotoxin A has not been neutralized and thus has been able to exert its toxic action from the start of the infection. By 20 h postinfection, irreversible damage has occurred and the host succumbs to the infection in spite of chemotherapy (42) . A number of exotoxin A toxoids (1; Cryz et al., in press) as well as vaccines from other pseudomonas virulence factors (10, 14, 17, 39) or cellular products (33) have been prepared and tested in vivo in various laboratories with positive results.
In a collaborative effort with Cryz and co-workers (in press), we were able to show protection of mice immunized with a different formalinized toxoid. Abe et al. (1) was able to protect mice against infection of at least 50 LD50 of purified exotoxin A. Although the present data regarding an exotoxin A toxoid vaccine indicates that it offers a considerable protection against pseudomonas infections, the role and efficacy of such a single component vaccine in protection of patients are still unclear. Existing data indicate that possibly proteases (7, 15, 17, 20, 32) 
